诺和诺德(NVO.US)联手OpenAI！剑指药物研发与效率革命

智通财经04-14

丹麦制药巨头诺和诺德(NVO.US)周二表示，正在与OpenAI合作，将人工智能(AI)部署到其从药物发现到生产制造及商业运营等各项业务中。诺和诺德表示，此次合作将利用OpenAI的技术分析复杂数据集、识别有潜力的候选药物，并提高生产制造、供应链、分销及企业运营的效率。诺和诺德未披露协议的财务条款。该公司表示，将在研发、制造及商业运营等领域启动试点项目，并计划在2026年底前实现全面整合。诺和诺德...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2627416842?lang=zh_CN&edition=full","thumbnail":"https://community-static.tradeup.com/news/f37d32b0a99033a3e267690b0a1c9421","is_english":false,"pubTime":"2026-04-14 16:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627416842","market":"us","top_or_hot":-1,"title":"诺和诺德(NVO.US)联手OpenAI！剑指药物研发与效率革命","media":"智通财经","content":"<div>\n<p>丹麦制药巨头诺和诺德(NVO.US)周二表示，正在与OpenAI合作，将人工智能(AI)部署到其从药物发现到生产制造及商业运营等各项业务中。诺和诺德表示，此次合作将利用OpenAI的技术分析复杂数据集、识别有潜力的候选药物，并提高生产制造、供应链、分销及企业运营的效率。诺和诺德未披露协议的财务条款。该公司表示，将在研发、制造及商业运营等领域启动试点项目，并计划在2026年底前实现全面整合。诺和诺德...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1428258.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺和诺德(NVO.US)联手OpenAI！剑指药物研发与效率革命</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺和诺德(NVO.US)联手OpenAI！剑指药物研发与效率革命\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-14 16:19 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1428258.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>丹麦制药巨头诺和诺德(NVO.US)周二表示，正在与OpenAI合作，将人工智能(AI)部署到其从药物发现到生产制造及商业运营等各项业务中。诺和诺德表示，此次合作将利用OpenAI的技术分析复杂数据集、识别有潜力的候选药物，并提高生产制造、供应链、分销及企业运营的效率。诺和诺德未披露协议的财务条款。该公司表示，将在研发、制造及商业运营等领域启动试点项目，并计划在2026年底前实现全面整合。诺和诺德...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1428258.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756168.USD","symbol_name":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1428258.html","article_id":"2627416842","we_media_id":null,"thumbnails":["https://community-static.tradeup.com/news/f37d32b0a99033a3e267690b0a1c9421"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627416842","pubTimestamp":1776154770,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"丹麦制药巨头$诺和诺德$周二表示，正在与OpenAI合作，将人工智能部署到其从药物发现到生产制造及商业运营等各项业务中。诺和诺德表示，此次合作将利用OpenAI的技术分析复杂数据集、识别有潜力的候选药物，并提高生产制造、供应链、分销及企业运营的效率。诺和诺德未披露协议的财务条款。诺和诺德表示，OpenAI还将帮助培训其全球员工队伍，提高AI素养，并提升各部门的生产效率。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","NVOX":"2倍做多NVO ETF-Defiance","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","NVO":"诺和诺德","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4599":"减肥药","BK4588":"碎股","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4585":"ETF&股票定投概念","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","NVOH":"Novo Nordisk A/S B Shares ADRhedged","BK4007":"制药","BK4532":"文艺复兴科技持仓"},"translate_title":"Novo Nordisk (NVO.US) Teams Up With OpenAI! Sword Finger Drug R&D and Efficiency Revolution","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVOX":0.6,"NVO":1.97,"NVOH":0.6},"content_text":"丹麦制药巨头诺和诺德(NVO.US)周二表示，正在与OpenAI合作，将人工智能(AI)部署到其从药物发现到生产制造及商业运营等各项业务中。诺和诺德表示，此次合作将利用OpenAI的技术分析复杂数据集、识别有潜力的候选药物，并提高生产制造、供应链、分销及企业运营的效率。诺和诺德未披露协议的财务条款。该公司表示，将在研发、制造及商业运营等领域启动试点项目，并计划在2026年底前实现全面整合。诺和诺德表示，OpenAI还将帮助培训其全球员工队伍，提高AI素养，并提升各部门的生产效率。制药企业正越来越多地使用AI来优化药物开发中较为繁琐的环节，例如寻找临床试验参与者、选择试验地点以及准备监管申报文件。不过，业内高管表示，这项技术在发现重大新分子这一更具挑战性的任务上尚未完全兑现潜力。诺和诺德首席执行官迈克·杜斯特达在接受采访时表示：“我们的目标不是取代科学家，而是增强他们的能力。”杜斯特达称，此次合作并非旨在削减诺和诺德当前员工规模，而是提升生产效率，并放缓未来招聘节奏。杜斯特达称，AI将帮助员工更快、更高效地工作，从而减少像过去那样大规模扩充人员的需求。在去年接任诺和诺德首席执行官不久后，杜斯特达曾宣布一项重组计划，裁减了9000个岗位。OpenAI首席执行官萨姆·奥尔特曼在声明中表示：“AI正在重塑各个行业，而在生命科学领域，它可以帮助人们活得更好、更长久。这项与诺和诺德的合作将帮助其加速科学发现、实现更智能的全球运营，并重新定义患者护理的未来。”诺和诺德补充称，此次合作包含了严格的数据保护、治理和人工监督措施，并建立在公司与其他技术合作伙伴和研究机构现有的AI计划基础之上。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627416842","isCrawlerRequest":true}